Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.53 |
| ▸ | PRKDC | P78527 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | HCK | P08631 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093476 | 0.83 | VRK1 (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL152637 | 0.80 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16655157 | 0.80 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL11405 | 0.79 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL10855 | 0.79 | MAP4K4 (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917286 | 0.79 | FGFR1 (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16665695 | 0.78 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL11325 | 0.78 | PIK3CG (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL9010 | 0.77 | PIK3CG (0.54) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL11928101 | 0.77 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| CN-106661019-B | Indolizine derivatives as phosphoinositide 3-kinase inhibitors | 奇斯药制品公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| US-20170334919-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9745306-B2 | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-29 | — | — | US | disclosed |
| EP-2970293-B1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-06-14 | — | — | EP | disclosed |
| US-9556184-B2 | Phosphoinositide 3-kinase inhibitors | Respivert, Ltd. (GB) | 2017-01-31 | — | — | US | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-20160090389-A1 | Phosphoinositide 3-Kinase Inhibitors | RESPIVERT LTD. (GB) | 2016-03-31 | — | — | US | disclosed |
| US-20160039826-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-9227977-B2 | Phosphoinositide 3-kinase inhibitors | RESPIVERT LTD. (GB) | 2016-01-05 | — | — | US | disclosed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014140597-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274980-A1 | COMPOUND | RESPIVERT LTD. (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039826-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PI4KB, PI4KA, IRAK3 | PIK3CD 16/4885PIK3CG 15/4885PIK3CA 8/4885 |
| US-20170334919-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PI4KB, IRAK3, PI4KA | PIK3CD 22/4885PIK3CG 17/4885PIK3CA 7/4885 |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIP4K2A | PIK3CD 15/4885PIK3CG 17/4885PIK3CA 14/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 8/4885PIK3CA 6/4885 |
| US-20140274980-A1 | COMPOUND | TNF, IL5, CCL11 | PIK3CD 4486/4885PIK3CG 4155/4885PIK3CA 4164/4885 |
| US-20160090389-A1 | Phosphoinositide 3-Kinase Inhibitors | PIK3CA, PIKFYVE, PIK3CB | PIK3CD 4/4885PIK3CG 5/4885PIK3CA 1/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CD 103/4885PIK3CG 126/4885PIK3CA 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.